Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025

Rhea-AI Summary

Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), will host a business update conference call on August 13, 2025, at 8:30 AM ET.

The call will feature CEO Lishan Aklog discussing business operations and growth strategy, while CFO Dennis McGrath will present Q2 2025 financial results. Investors can access the webcast through luciddx.com or join by phone using specific dial-in numbers for U.S. and international callers.

Conference Call and Webcast at 8:30 AM Eastern Time

NEW YORK, July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2025 financial results.

The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard^® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck^® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-august-13-2025-302516614.html

SOURCE Lucid Diagnostics

FAQ

When is Lucid Diagnostics (LUCD) Q2 2025 earnings call scheduled?

Lucid Diagnostics' business update and earnings call is scheduled for Wednesday, August 13, 2025, at 8:30 AM ET.

How can investors access the Lucid Diagnostics (LUCD) conference call?

Investors can access the call via webcast at luciddx.com or by phone: U.S. callers dial 1-800-836-8184 and international callers dial 1-646-357-8785. Use conference name 'Lucid Diagnostics Business Update'.

Who will be presenting at the Lucid Diagnostics (LUCD) Q2 2025 earnings call?

Lishan Aklog, M.D., Chairman and CEO, will provide a business update and growth strategy overview, while Dennis McGrath, CFO, will discuss Q2 2025 financial results.

How long will the Lucid Diagnostics (LUCD) earnings call replay be available?

The conference call replay will be available for 30 days on the investor relations section of luciddx.com.